The authors report a living zebrafish model that allowed the visualization the metastatic cancer cell killing effect by tumor- infiltrating lymphocytes (TILs) and CAR-T cells in vivo at the single-cell level. In a freshly isolated primary human melanoma, specific TILs effectively eliminated metastatic cancer cells in the living body.
[Proceedings of the National Academy of Sciences of the United States of America]
The Province of Alberta and the Alberta Cancer Foundation said that they were teaming up to invest $15 million to offer the leading edge therapy that sees a patient’s own immune cells genetically reprogrammed to attack cancer cells in their body.
The authors developed a novel mechanistic model of immune and antitumor responses to the T-cell bispecifics, including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor.
[npj Systems Biology and Applications]
[zotpress userid=’6445212′ items=’7Q3VUWIV’ style=’apa’ cite=’yes’]
Scientists found that NK cells in aggressive B cell lymphoma underwent substantial transcriptional reprogramming associated with increased lipid metabolism, including elevated expression of the transcriptional regulator PPAR-g.
[zotpress userid=’6445212′ items=’KCG8HNY6′ style=’apa’ cite=’yes’]
The authors focus on the current state of the most promising non‐viral gene delivery techniques, including electroporation and transfection with cationic polymers or lipids.
[zotpress userid=’1254621′ items=’N6YUT75H’ style=’apa’ cite=’yes’]
A complex network of interactions between angioimmunoblastic lymphoma (AITL) tumor cells and the various cells of the tumor microenvironment has impeded the study of AITL pathogenesis in vitro. The authors provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human AITL.
[zotpress userid=’6630899′ items=’XGQ2KSKM’ style=’apa’ cite=’yes’]
The authors found that the different sites of extranodal involvement may affect response, overall survival, and progression-free survival in patients with relapsed or refractory non-Hodgkin lymphoma treated with anti-CD19 CAR-T cells.
[Frontiers of Medicine]
[zotpress userid=’1254621′ items=’Y77EB8IA’ style=’apa’ cite=’yes’]
The authors provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human angioimmunoblastic lymphoma (AITL). In addition, they give an overview of preclinical models that recapitulate more or less faithfully human AITL characteristics and pathology.
[zotpress userid=’1254621′ items=’8CIEH8DQ’ style=’apa’ cite=’yes’]
TG Therapeutics, Inc. announced that the FDA has accepted the company’s New Drug Application for umbralisib, the company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma who have received at least one prior anti-CD20 based regimen and follicular lymphoma who have received at least two prior systemic therapies.
[TG Therapeutics, Inc.]
BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
Scientists treated 14 relapsed or refractory diffuse large B-cell lymphoma patients by combining autologous hematopoietic stem cell transplantation and anti-CD19 chimeric antigen receptor T-cell therapy.
[zotpress userid=’1254621′ items=’7W99HMR7′ style=’apa’ cite=’yes’]